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1. Introduction 
Gougerotin (I), a dipeptidyl pyrimidine nucleoside 
antibiotic, has been found to specifically inhibit the 
step of protein biosynthesis which is catalyzed by 
ribosomal peptidyl transferase [l-S] . Since three 
gougerotin analogues have been synthesized recently 
[6] , 1-[3(sarcosyl-D-seryl-)amino3-deoxy$-D-gluco- 
pyranosyl-)uracil (II, cf. fig. l), I-[3-(sarcosyl-D- 
seryl-)amino-3-deoxy-P-D-glucopyranosyl-)cytosine 
(III) and l-[4-(sarcosyl-D-seryl-)amino-4-deoxy-O-D- 
glucopyranosyl-)cytosine (IV), we made an attempt 
to characterize the mechanism of action of gougerotin 
(I) and its analogues (II-IV) on the activity of ribo- 
somal peptidyl transferase. The results are presented 
below, together with a discussion of relationships be- 
tween structures I-IV and their inhibitory activity. 
2. Materials and methods 
Ribosomes were prepared from Escherichia coli B 
as described elsewhere [7]. Gougerotin was purchased 
from Calbiochem USA. The gougerotin analogues 
were prepared according to Lichtenthaler et al. [6]. 
2.1. Transfer assay with (Lys),-tRNA 
The transfer of lysine peptides from (Lys),-tRNA 
to puromycin was measured according to Rychlik et 
al. [7] . The incubation lasted 40 min at 35”. The 
samples were precipitated with 2.5% trichloroacetic 
acid, filtered and counted. 
2.2. Transfer assay with AcPhe-tRNA 
The transfer of the AcPhe-residue from AcPhe- 
tRNA to puromycin was measured according to [7]. 
Fig. 1. Formulas of gougerotin (I) and its analogues (II-IV). 
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After a 30 min incubation period at 35”, the 
AcPhe-puromycin formed was extracted into ethyl 
acetate [8] as modified by Monro, eernri and Marcker 
[91. 
2.3. Transfer assay with the CACCA-(AcLeu) frag- 
ment 
The transfer of the AcLeu residue from the 
CACCA-(AcLeu) fragment to puromycin was meas- 
ured according to Monro et al. [9]. 
For assay of CACCA-(AcLeu) binding to the 
donor site, the procedure of Celma, Monro and 
Vazquez [4] was used, whereas CACCA-(Phe) 
binding to the acceptor site was assayed according to 
Pestka [5]. 
3. Results 3.2. The effect of gougerotin analogues 
3 .l . The effect of gougerotin on the transfer reaction 
Gougerotin inhibits the activity of ribosomal pep- 
tidy1 transferase. The most pronounced effect of 
gougerotin was observed in the case of the fragment 
reaction, i.e. the transfer of the AcLeu residue from the 
CACCA-(AcLeu) fragment to puromycin (fig. 2). 
The transfer of the AcPhe residue or of lysine peptides 
to puromycin which takes place on the 70 S ribo- 
somes with intact molecules of either AcPhe-tRNA 
or (Lys),-tRNA and with appropriate messenger RNA, 
was less sensitive towards gougerotin action (fig. 3). 
In this case gougerotin caused a 50% inhibition of 
transferase activity at a concentration higher by one 
order of magnitude than in the case of inhibition of 
the fragment reaction. The time course of the effect 
of gougerotin on the transfer of lysine peptides to 
puromycin is shown in fig. 4. The time course of its 
effect on the transfer of the AcLeu-residue from the 
CACCA-(AcLeu) fragment is presented in fig. 5. 
Only one of the gougerotin analogues (IV in fig. 1) 
inhibited the activity of peptidyl transferase (fig. 2 
and 3). It had a weaker effect than gougerotin. Fig. 4 
shows the time course of the effect of the gougerotin 
Fig. 2. Effect of gougerotin analogue (IV) and of gougerotin on the fragment reaction of AcLeu-pentanucleotide with puromycin 
Reaction mixtures contained ribosomes (100 ccg protein), and about 0.1 rmole AcLeu-pentanucleotide (1200 cpm); other com- 
ponents of the reaction mixture, conditions and procedure were described in [9]. The amount of formed AcLeu-puromycin was 
determined as the difference between radioactivity extracted into ethyl acetate after incubation with puromycin. Log M, concen- 
tration of gougerotin derivative or of gougerotin (concentration calculated on basis of final volume after addition of methanol). 
%, AcLeu-puromycin formation as % of control without inhibitor (about 1000 cpm transferred); u, gougerotin, M, 
analogue (IV). 
!‘ig. 3. The effect of gougerotin analogue (IV) and of gougerotin on the transfer of lysine peptides from (Lys),-tRNA and of 
AcPhe-residue from AcPhe-tRNA to puromycin. The reaction mixture contained (Lys),-tRNA (10 fig, 1880 cpm) or AcPhe- 
tRNA (20 pgg, 1920 cpm). In control experiments 65% of lysine peptides from added (Lys),-tRNA and 50% of AcPhe-residue 
from added AcPhe-tRNA were transferred to puromycin. Log M, concentration of gougerotin analogue or of gougerotin. %, 
(Lys),-puromycin or AcPhe-puromycin formed as percentage of control without inhibitor. u, AcPhe-tRNA + gougerotin; 
u, (Lys),-tRNA + gougerotin; U, AcPhe-tRNA + analogue (IV); -1, (Lys),-tRNA + analogue (IV). 
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Fig. 4. The time course of the effect of gougerotin analogue 
(IV) and of gougerotin on the fragment reaction of AcLeu- 
pent~ucleot~de with puromycin. Experimental conditions as 
in fig. 2. %, amount of AcLeu-residue transferred to puromycin 
as percentage of AcLeu-pentanucleotide added. o--o, 
CACCA-(AcLeu) + puromycin; -, the effect of 6.6 X lo* 
M gougerotin; M, the effect of iOe3 M gougerot~; n - - - h, 
the effect of 6.6 X lo4 M analogue (IV); 4 - - - A, the effect 
of 2 X low3 M of derivative (IV). - 
analogue (IV) on the transfer of lysine peptides to 
puromycin, fig. 5 its effect on the transfer of AcLeu- 
residue from the CACCA-(AcLeu) fragment. The 
gougerotin analogues II and III had no i~ibito~ 
effect on peptidyl transferase at any concentration 
tested. 
Neither gougerotin itself, nor its analogues were 
acceptors of the transferred acylaminoacyl residue, 
i.e. the inhibition of peptidyl transferase was not 
caused by a puromycin-lye action. This finding is in 
agreement with the absence of a free (r-NH2 or &-OH 
group in the compounds studied. 
3.3. The effect of gougerotin and its analogue on the 
CACCA -(AcLeu) binding to the donor site 
The gougerotin analogue (IV) which inhibited the 
transfer of the peptide moiety to puromycin, stimu- 
lated the binding of the donor substrate CACCA- 
(AcLeu) to the donor site (table I). It has a similar, 
although lower, effect as the parent compound 
gougerotin. 
Fig. 5. The time course of the effect of gougerotin analogue 
(IV) and of gougerotin on the transfer of lysine peptides from 
(Lys)n-tRNA to puromycin. Experimental conditions as in 
fg 3. %, amount of lysine peptides transferred to puromycin 
as percentage of (Lys),-tRNA added; time in minutes. 
o---o, puromycin IO4 M; o----o, puromycin lo4 M + 
analogue (IV) 10” M; +--+ puromycin lo4 M + gougero- 
tin 10e3 M. 
3.4. The effect of gougerotin and its analo~e on the 
CACCA-(Phe) binding to the acceptor site 
The gougerotin analogue IV inhibited the binding 
of the acceptor substrate CACCA-(Phe) to the 
acceptor site of peptidyl transferase (table 1). In this 
case the effect of the analogue was also lower than the 
effect of gougerotin. 
4. Discussion 
The gougerotin analogues, which were tested as to 
their effect on peptidyl transferase, differ from the 
parent compound in several respects. in all of them 
the glucuronic acid amide is replaced by aminoglucose, 
i.e. the analogues contain a -CH2 OH group on the 6’ 
carbon instead of a carboxamide -CONH2 grouping. 
In compounds II and III the sarcosyl-D-se@ amide 
residue is bound to the 3’.carbon of glucose, whereas 
in compound IV the sarcosyl-D-se@ residue is bound 
to the 4’-carbon. 
Replacement of the -CONH2 group of gougerotin 
by a -CH20H group in the analogue IV decreases the 
inhibitory activity approximately 10 times. This may 
indicate that the carboxamide group increases the 
affinity of the compounds in question to the active 
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Table 1 
The effect of gougerotin and analogue (IV) on the CACCA-(AcLeu) and CACCA-Phe binding to ribosomes. 
-- 
Concn. 
CACCA-(AcLeu) binding CACCA-Phe binding 
M 
cpm % cpm % 
Control _ 345 100 2680 100 
Gougerotin lo4 535 155 2168 81 
1o-3 565 164 1256 47 
Analogue (IV) 1o-3 357 104 2567 96 
2 x 1o-3 385 112 2243 80 
--- 
Assay of CACCA-(AcLeu) binding was determined according to Celma et al. [4] The incubation mixture containing CACCA- 
(Ac-‘4C-Leu) (2200 cpm, specific activity 83 mCi/mmole) and 70 S ribosomes (390 ug protein) was incubated at 0’ 40 min. 
Assay of CACCA-Phe binding was determined according to Pestka [lo] The reaction mixture containing CACCA-3H-Phe 
(10700 cpm, specific activity 21 Ci/mmole), 70 S ribosomes (170 pg protein) and 20% ethanol (v/v) incubated at 24’ for 20 min. 
The amount of bound substrate was calculated by difference of parallel incubations with and without ribosomes. 
site of peptidyl transferase, though the grouping itself 
is not directly involved in the inhibitory mechanism. 
The position of the sarcosyl-D-seryl amide residue on 
the glucose moiety appears to be more important. 
Peptidyl transferase was inhibited only by compounds 
which had this residue attached on the 4’carbon of 
glucose or its derivative (compounds I and IV). 
Derivatives with the sarcosyl-D-seryl amide chain 
attached to the 3’carbon did not show any inhibitory 
effect on peptidyl transferase. 
It has been proved recently [2,7,9] that the active 
site of peptidyl transferase is composed of two binding 
sites, the donor and the acceptor site, which specifical- 
ly interact with the donor and acceptor substrate 
respectively. At concentrations which inhibit the 
transfer of an acylaminoacyl group, gougerotin and 
compound IV increase the amount of donor substrate 
bound to the donor site and decrease the amount of 
acceptor substrate at the acceptor site. For this reason 
we suggest hat gougerotin and its derivative inhibit 
peptidyl transferase by competing with the acceptor 
substrate at the acceptor site. This view is in accord- 
ance with the fact that the structure of the two 
compounds is similar to that of 2’(3’)- O-aminoacyl 
cytidine, which is a good acceptor substrate in the 
reaction catalyzed by peptidyl transferase [7]. The 
increased binding of the donor substrate to the donor 
site may be caused by a conformation change at the 
donor site which occurs when the acceptor site has 
been occupied by the acceptor substrate. 
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